MET and neoplasm: This fusion protein acts as an aberrant transcription factor, upregulating the MET proto-oncogene receptor tyrosine kinase (MET) signaling pathway, which promotes tumor proliferation, angiogenesis, and early metastasis, making this axis a promising therapeutic target (2–4).